Commentary
Using Global Burden of Disease data, P. Golabi et al. (Inova Health System, USA) aimed to assess the incidence, mortality, and disability-adjusted life years attributable to NAFLD-related liver complications in Asia, the Middle East and North Africa.
As stated by the authors in their conclusion, “NAFLD is poised to contribute to a substantial liver disease burden in these regions.”
